|Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients|
A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ...
Nature medicine 23 (6), 703-713, 2017
|Tumor mutational load predicts survival after immunotherapy across multiple cancer types|
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
|IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype|
S Turcan, D Rohle, A Goenka, LA Walsh, F Fang, E Yilmaz, C Campos, ...
Nature 483 (7390), 479-483, 2012
|Tumor and microenvironment evolution during immunotherapy with nivolumab|
N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba, JS Sims, FS Hodi, ...
Cell 171 (4), 934-949. e16, 2017
|Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy|
D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ...
Science 359 (6375), 582-587, 2018
|Safety recommendations for evaluation and surgery of the head and neck during the COVID-19 pandemic|
B Givi, BA Schiff, SB Chinn, D Clayburgh, NG Iyer, S Jalisi, MG Moore, ...
JAMA otolaryngology–head & neck surgery 146 (6), 579-584, 2020
|The head and neck cancer immune landscape and its immunotherapeutic implications|
R Mandal, Y Şenbabaoğlu, A Desrichard, JJ Havel, MG Dalin, N Riaz, ...
JCI insight 1 (17), 2016
|The increasing incidence of thyroid cancer: the influence of access to care|
LGT Morris, AG Sikora, TD Tosteson, L Davies
Thyroid 23 (7), 885-891, 2013
|The mutational landscape of adenoid cystic carcinoma|
AS Ho, K Kannan, DM Roy, LGT Morris, I Ganly, N Katabi, D Ramaswami, ...
Nature genetics 45 (7), 791-798, 2013
|Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation|
LGT Morris, AM Kaufman, Y Gong, D Ramaswami, LA Walsh, Ş Turcan, ...
Nature genetics 45 (3), 253-261, 2013
|Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus–associated oropharyngeal cancer|
LGT Morris, AG Sikora, SG Patel, RB Hayes, I Ganly
Journal of clinical oncology 29 (6), 739, 2011
|Characterization of HPV and host genome interactions in primary head and neck cancers|
M Parfenov, CS Pedamallu, N Gehlenborg, SS Freeman, L Danilova, ...
Proceedings of the National Academy of Sciences 111 (43), 15544-15549, 2014
|Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response|
R Mandal, RM Samstein, KW Lee, JJ Havel, H Wang, C Krishna, ...
Science 364 (6439), 485-491, 2019
|Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance|
RM Tuttle, JA Fagin, G Minkowitz, RJ Wong, B Roman, S Patel, B Untch, ...
JAMA Otolaryngology–Head & Neck Surgery 143 (10), 1015-1020, 2017
|Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapy|
NG Iyer, LGT Morris, RM Tuttle, AR Shaha, I Ganly
Cancer 117 (19), 4439-4446, 2011
|Breast cancer methylomes establish an epigenomic foundation for metastasis|
F Fang, S Turcan, A Rimner, A Kaufman, D Giri, LGT Morris, R Shen, ...
Science translational medicine 3 (75), 75ra25-75ra25, 2011
|Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS)|
AS Ho, EE Sarti, KS Jain, H Wang, IJ Nixon, AR Shaha, JP Shah, ...
Thyroid 24 (5), 832-839, 2014
|Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors|
D Jethanamest, LG Morris, AG Sikora, DI Kutler
Archives of Otolaryngology–Head & Neck Surgery 133 (3), 276-280, 2007
|Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway|
Z Li, P Razavi, Q Li, W Toy, B Liu, C Ping, W Hsieh, F Sanchez-Vega, ...
Cancer cell 34 (6), 893-905. e8, 2018
|A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy|
E Tolosa, I Litvan, GU Höglinger, D Burn, A Lees, MV Andrés, ...
Movement Disorders 29 (4), 470-478, 2014